PHARMAIDS PHARMACEUTICALS

BSE: 524572 22 Aug 2025

Healthcare

₹ 62

Pharmaids Pharmaceuticals Ltd. specializes in Pharmaceuticals within the Healthcare sector.

PHARMAIDS PHARMACEUTICALS

BSE: 524572 22 Aug 2025

Healthcare

₹ 62

Pharmaids Pharmaceuticals Ltd. specializes in Pharmaceuticals within the Healthcare sector.

Book Value

18.1

Dividend Yield

0.0%

Debt to Equity

0.62

Stock P/E

Market Cap

204.0 Cr

PHARMAIDS PHARMACEUTICALS - Share Price & Details

Market Cap

₹204.0

High /Low

87.5 / 31.9

Stock P/E

Book Value

₹18.1

Dividend Yield

0.0

ROCE

-6.87

ROE

₹-10.8

Face Value

10.0

PEG Ratio

EVEBITDA

₹-39.0

Debt

39.7

CMP / FCF

-14.5

Debt to equity

₹0.62

NP Ann

-7.28

High price all time

87.5

Piotroski score

₹4.0

Graham Number

No. Eq. Shares

3.53

Net CF

₹-1.99

Net profit

-7.28

Price to book value

3.2

Interest Coverage

₹-3.0

Low price all time

1.58

Industry PE

33.8

Reserves

₹28.5

Free Cash Flow

₹-16.8

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
Shyama Computronics and Servic	1.48	0.93	0.67	0.00	5.33	35.5
Triochem Products Ltd.,	3.25	-4.52	NA	-18.44	0
PHARMAIDS PHARMACEUTICALS LTD.	11.39	-30.56	1.33	-0.86	204.0
PANCHSHEEL ORGANICS LTD.	283.74	31.71	283.74	2.41	201	14.9
Aashka Hospitals Limited	NA	NA	NA	NA	193	77.5

Peer Comparison Chart

About PHARMAIDS PHARMACEUTICALS

Pharmaids Pharmaceuticals Ltd., with Security Code 524572, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Latest News

Pharmaids Pharmaceuticals reports consolidated net loss of Rs 4.95 crore in the June 2025 quarter

(08 Aug 2025)

Net Loss of Pharmaids Pharmaceuticals reported to Rs 4.95 crore in the quarter ended June 2025 as against net loss of Rs 2.68 crore during the previous...

Pharmaids Pharmaceuticals reports standalone net loss of Rs 4.36 crore in the June 2025 quarter

(08 Aug 2025)

Net Loss of Pharmaids Pharmaceuticals reported to Rs 4.36 crore in the quarter ended June 2025 as against net loss of Rs 1.62 crore during the previous...

Zim Laboratories reports consolidated net loss of Rs 1.87 crore in the June 2025 quarter

(08 Aug 2025)

Sales decline 12.30% to Rs 71.76 crore.

Aeonx Digital Technology consolidated net profit declines 18.33% in the June 2025 quarter

(08 Aug 2025)

Net profit of Aeonx Digital Technology declined 18.33% to Rs 0.49 crore in the quarter ended June 2025 as against Rs 0.60 crore during the previous quarter...

Pharmaids Pharmaceuticals Reports Mixed Financial Results Amid Sales Growth and Profitability Challenges in June 2025

(08 Aug 2025)

Pharmaids Pharmaceuticals has announced its financial results for the quarter ending June 2025, showcasing significant growth in net sales at Rs 6.66 crore.

Ashish Polyplast standalone net profit rises 18.18% in the June 2025 quarter

(08 Aug 2025)

Net profit of Ashish Polyplast rose 18.18% to Rs 0.39 crore in the quarter ended June 2025 as against Rs 0.33 crore during the previous quarter ended June...

Quarterly Table

Standalone Consolidated

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.8	1.2	0.1
Expenses	0.7	8.6	1.6	1.0	1.3	1.8	1.9	2.0	2.9	2.8
Operating Profit	-0.7	-8.6	-1.6	-1.0	-1.3	-1.8	-1.7	-1.1	-1.7	-2.7
OPM %	0%	0%	0%	0%	-6166.67%	-25814.29%	-1027.54%	-135.37%	-143.13%	-2000%
Other Income	0.0	0.0	0.4	-0.3	-0.9	0.0	0.0	0.0	0.0	1.0
Interest	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	2.1
Depreciation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1
Profit before tax	-0.7	-8.6	-1.2	-1.3	-2.2	-2.1	-1.8	-1.2	-1.8	-3.8
Tax %	0.4%	-28.4%	7.8%	-60.8%	-26.1%	6.1%	-8.5%	-15.2%	-13.7%	0%
Net Profit	-0.7	-6.2	-1.3	-0.5	-1.6	-2.2	-1.6	-1.0	-1.6	-3.1
EPS in Rs	-0.5	-4.79	-0.58	-0.23	-0.73	-0.99	-0.46	-0.29	-0.45	0

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	0.0	0.0	0.0	0.0	5.8	4.7	5.2	4.7	4.8
Expenses	8.6	1.6	1.0	1.3	11.4	8.1	7.8	7.6	8.7
Operating Profit	-8.6	-1.6	-1.0	-1.3	-5.6	-3.4	-2.6	-2.9	-3.9
OPM %	0%	0%	0%	-6166.67%	-96.09%	-72.88%	-48.81%	-61.27%	-81.88%
Other Income	0.0	0.4	-0.3	-0.9	0.1	-0.1	-0.1	0.0	0.1
Interest	0.0	0.0	0.0	0.0	0.8	0.3	0.3	0.5	1.0
Depreciation	0.0	0.0	0.0	0.0	0.6	0.6	0.6	0.6	0.6
Profit before tax	-8.6	-1.2	-1.3	-2.2	-6.9	-4.2	-3.5	-4.0	-5.5
Tax %	-28.4%	7.8%	-60.8%	-26.1%	-7.8%	-27.4%	-28.1%	-24.9%	0%
Net Profit	-6.2	-1.3	-0.5	-1.6	-6.3	-3.1	-2.6	-3.0	-4.8
EPS in Rs	-4.76	-0.58	-0.23	-0.73	-2.82	-0.76	-0.73	-0.55	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	-32%
5 Years:	-44%
3 Years:	-85%
TTM:	11000%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	29%

Stock Price CAGR
10 Years:	32%
5 Years:	67%
3 Years:	77%
1 Year:	11%

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	102050%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	-34%

Stock Price CAGR
10 Years:	32%
5 Years:	67%
3 Years:	77%
1 Year:	11%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

PHARMAIDS PHARMACEUTICALS

PHARMAIDS PHARMACEUTICALS

PHARMAIDS PHARMACEUTICALS - Share Price & Details

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About PHARMAIDS PHARMACEUTICALS

Latest News

Pharmaids Pharmaceuticals reports consolidated net loss of Rs 4.95 crore in the June 2025 quarter

Pharmaids Pharmaceuticals reports standalone net loss of Rs 4.36 crore in the June 2025 quarter

Zim Laboratories reports consolidated net loss of Rs 1.87 crore in the June 2025 quarter

Aeonx Digital Technology consolidated net profit declines 18.33% in the June 2025 quarter

Pharmaids Pharmaceuticals Reports Mixed Financial Results Amid Sales Growth and Profitability Challenges in June 2025

Ashish Polyplast standalone net profit rises 18.18% in the June 2025 quarter

What are analysts’ price targets for VRNA in the next 12 months - Boost your returns with professional guidance

What markets is REVB expanding into Is GGAL stock a good long term investment option - Massive portfolio appreciation

Is AMPGW a good long term investment - Skyrocketing investment returns

What drives VEON Ltd. Depositary Receipt stock price - Powerful profit generation

How does Safe Pro Group Inc. generate profit in a changing economy - Value Investing Picks For Every Investor

What makes SRFM stock price move sharply - Turn market volatility into profit opportunities

How does PRVA compare to its industry peers - Take advantage of unprecedented market momentum

What institutional investors are buying NiSource Inc. stock - Capitalize on market momentum for profits

What is the risk reward ratio of investing in SPKLW stock - Invest confidently with professional market insights

Is Xylo Technologies Ltd Depositary Receipt a growth stock or a value stock - Real-time trading signals for maximum returns

Should I hold or sell ESSA stock in 2025 - Consistently superior profits

Is Launch One Acquisition Corp. Debt Equity Composite Units a good long term investment - Free Investment Risk Control

What analysts say about iHuman Inc. Depositary Receipt stock - Consistent wealth multiplication

Sustainable Investment Stocks in India Elite Investment Community Insights - Consistent double returns

Siyaram Silk Mills Limited (SIYSIL) Hits 52 Week High - Free Bull & Bear Market Updates

Best Stocks for Value Investors AI Driven Stock Analysis Reports - Free Capital Efficiency Planning

Similarweb Ltd. Stock Analysis and Forecast - Exceptional earning trajectories

Bullish Pattern Emerging on STL Global Limited (SGL) - Lightning-fast capital gains

Macro Trends and Their Impact on IMP Powers Limited (517571) - Free Risk Assessment Services

Surmodics Inc. Stock Analysis and Forecast - Exceptional growth trajectory

Investing in Infrastructure Boom Expert Stock Recommendations - Unprecedented profits

N.K Industries Limited (NKIND)’s Trend in 2025 - Phenomenal capital gains

What analysts say about ASPN stock - High-yield capital appreciation

Would You Accumulate or Wait on Osia Hyper Retail Limited (OSIAHYPER) - Skyrocketing investment returns

Best Electric Vehicle Stocks in India Smart Investment Choices - Free Investment Community

What analysts say about Mesoblast Limited Depositary Receipt stock - Exponential wealth increase

NVNIW Stock Analysis and Forecast - Free Wealth Planning Blueprint

Bullish Pattern Emerging on Ddev Plastiks Industries Limited (DDEVPLSTIK) - Superior stock selection

What drives Oxford Square Capital Corp. stock price - Accelerated capital growth

Top Stocks for Wealth Management Best Investment Portfolio Ideas - Consistently high yield

Company Inc. Equity Warrant stock - Lightning-fast capital gains

AVF CL Stock Analysis and Forecast - Accelerated earnings growth

India’s Best Performing Stocks for the Last Decade Pro Investor Picks - Outstanding capital returns

OCCL Limited (OCCLLTD) Sees Unusual Trading Volume - Free Investment Case Studies

Pharmaids Pharmaceuticals Faces Short-Term Challenges Amid Strong Annual Performance

Pharmaids Pharmaceuticals Faces Mixed Financial Signals Amid Growth and Challenges

Camlin Fine Sciences reports consolidated net loss of Rs 0.72 crore in the March 2025 quarter

Pharmaids Pharmaceuticals reports consolidated net loss of Rs 3.94 crore in the March 2025 quarter

Pharmaids Pharmaceuticals Reports Mixed Financial Results Amidst Rising Costs and Strong Sales Growth in March 2025

Krishna Capital & Securities consolidated net profit declines 45.45% in the March 2025 quarter

S Chand & Company consolidated net profit rises 9.81% in the March 2025 quarter

Q4 results today: JSW Steel, Ashok Leyland, Glenmark Pharma on May 23

Q4 results today: JSW Steel, Ashok Leyland, Glenmark & others to declare earnings on May 23 — Full list here

Q4 results: JSW Steel, Aditya Birla Fashion, Ashok Leyland, Ashoka Buildcon, Reliance Infra and others to declare earnings today; check list

Pharmaids Pharmaceuticals Adjusts Evaluation Amid Mixed Performance Indicators and Challenges

Pharmaids Pharmaceuticals Faces Stability Amidst Operating Challenges and Debt Concerns

Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care

Prima Plastics consolidated net profit declines 51.04% in the December 2024 quarter

Q3 Results Today: HAL, PFC, RFC, Godrej Industries Among 500 Firms To Declare Earnings

Shankarappa Nagaraja Vinaya Babu proposed to acquire 26% stake in Pharmaids Pharmaceuticals Limited for approximately INR 570 million.

Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024

Pharmaids Pharma Reports Positive Q2 Results, Operating Cash Flow Declines

Emcure and MS Dhoni drive India’s fight against Anemia

Shares below Rs 100: Only buyers were seen in these stocks on November 19

Pharma industry expo to held from Nov 26 to 28 in Greater Noida

NBCC, Deepak Nitrite, Eicher Motors, Patel Engineering Among 650+ Companies To Declare Q2 Results Today

Pharmaids Pharmaceuticals' Stock Reaches All-Time High, Outperforms Sector and Sensex

Pharmaids Pharmaceuticals' Stock Surges to 52-Week High, Outperforming Sector by 4.88%

Pharmaids Pharmaceuticals Hits 52-Week High, Outperforms Sector and Sensex

Pharmaids Pharmaceuticals Surges to All-Time High, Outperforms Sector and Sensex

Shares below Rs 100: Only buyers were seen in these stocks on November 05

Shares below Rs 100: Only buyers were seen in these stocks on November 04

गिरते बाजार में मालामाल कर गए 100 रुपए के ये 5 स्टॉक, क्या कल मिलेगा मौका?

Shares below Rs 100: Only buyers were seen in these stocks on October 31

Shares below Rs 100: Only buyers were seen in these stocks on October 30